Table 4 Factors predicting LRR after NAC
Parameters | LRR | No LRR | P value |
|---|---|---|---|
(n = 104) | (n = 943) | ||
Age (years) | 0.66 | ||
≦50 | 55 (9.6%) | 520 (90.4%) | |
> 50 | 49 (10.4%) | 423 (89.6%) | |
Clinical T stage | 0.059 | ||
T1 | 5 (12.5%) | 35 (87.5%) | |
T2 | 51 (8.8%) | 531 (91.2%) | |
T3 | 16 (7.8%) | 189 (92.2%) | |
T4 | 32 (14.5%) | 188 (85.5%) | |
Clinical lymph node status | < 0.0001 | ||
N0 | 2 (2.5%) | 77 (97.5%) | |
N1 | 40 (7.4%) | 503 (92.6%) | |
N2 | 62 (14.6%) | 363 (85.4%) | |
SBR grade | 0.004 | ||
1 | 2 (2.6%) | 75 (97.4%) | |
2 | 38 (9.4%) | 367 (90.6%) | |
3 | 60 (12.9%) | 406 (87.1%) | |
Unknown | 4 (4.0%) | 95 (96.0%) | |
Histologic type | 0.083 | ||
Invasive ductal carcinoma | 100 (9.7%) | 928 (90.3%) | |
Invasive lobular carcinoma | 2 (20.0%) | 8 (80.0%) | |
Mucinous carcinoma | 0 | 4 (100.0%) | |
Others | 2 (40.0%) | 3 (60.0%) | |
Margin | 0.765 | ||
Free | 102 (10.1%) | 912 (89.9%) | |
Positive | 2 (6.1%) | 31 (93.9%) | |
ER | 0.001 | ||
Positive | 47 (7.4%) | 587 (92.6%) | |
Negative | 57 (13.8%) | 356 (86.2%) | |
PR | 0.003 | ||
Positive | 38 (7.2%) | 489 (92.8%) | |
Negative | 66 (12.7%) | 454 (87.3%) | |
HER2 | 0.722 | ||
Positive | 48 (10.3%) | 418 (89.7%) | |
Negative | 56 (9.6%) | 525 (90.4%) | |
Subtype | 0.043 | ||
HR + /HER2− | 33 (7.9%) | 386 (92.1%) | |
HR + /HER2 + | 19 (8.0%) | 218 (92.0%) | |
HR−/HER2 + | 29 (12.7%) | 200 (87.3%) | |
HR−/HER2− | 23 (14.2%) | 139 (85.8%) | |
Neoadjuvant regimens | 0.189 | ||
Anthracycline only | 7 (18.9%) | 30 (81.1%) | |
Taxane only | 6 (7.3%) | 76 (92.7%) | |
Anthracycline + taxane | 63 (10.4%) | 540 (89.6%) | |
Chemotherapy + target therapy | 28 (8.6%) | 297 (91.4%) | |
Operation type | 0.303 | ||
Mastectomy | 66 (10.7%) | 549 (89.3%) | |
BCS | 38 (8.8%) | 394 (91.2%) | |
pCR | 0.006 | ||
Yes | 12 (5.2%) | 220 (94.8%) | |
No | 92 (11.3%) | 723 (88.7%) |